Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic | Synapse

⌘+K

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Vaccination coverage, dropout and predictors of schedule-complete vaccination among children aged 0–59 months in Gushegu and Nanumba South districts, northern Ghana: A cross-sectional studyHuman Vaccines & Immunotherapeutics · 2026
2A qualitative evaluation of a STEAM (Science, technology, engineering, arts, and mathematics) peer education intervention on teenagers’ knowledge, confidence, and advocacy for HPV vaccine communicationHuman Vaccines & Immunotherapeutics · 2026
3From metastatic disease to no evidence of disease after conversion liver surgery in advanced gastric cancer with liver metastases: A case reportHuman Vaccines & Immunotherapeutics · 2026
4GMMA as adjuvant and carrier for mucosal delivery of group A streptococcus glycoconjugate vaccineHuman Vaccines & Immunotherapeutics · 2026
5HPV vaccination coverage and barriers for people with disability: A scoping reviewHuman Vaccines & Immunotherapeutics · 2026

Safety signals of tocilizumab in pediatric patients: A real-world pharmacovigilance analysis based on the FAERS database with network pharmacology insightsHuman Vaccines & Immunotherapeutics · 2026
Safety and immunogenicity of a first-generation modified vaccinia virus Ankara-vectored SARS-CoV-2 vaccine candidate with mRNA-based booster vaccination: A phase 1 trialHuman Vaccines & Immunotherapeutics · 2026
RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024Human Vaccines & Immunotherapeutics · 2026
Development of mRNA vaccines against herpes zosterHuman Vaccines & Immunotherapeutics · 2026
Safety of nirsevimab in children aged 0–24 months: Analysis based on EudraVigilance data (2023–2025)Human Vaccines & Immunotherapeutics · 2026

More from Human Vaccines & Immunotherapeutics

More from Punjab Agricultural University